ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2009
Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.Psychopharmacology · 2018Review
- Nicotinic receptor antagonists as treatments for nicotine abuse.Advances in pharmacology (San Diego, Calif.) · 2014Review
- Potential therapeutic uses of mecamylamine and its stereoisomers.Pharmacology, biochemistry, and behavior · 2013Review
- Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.The Journal of pharmacology and experimental therapeutics · 2012Article
- Nicotine as a potential neuroprotective agent for Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2012Review
- α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Pharmacological reviews · 2011Review
- Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.European journal of pharmacology · 2011Article
- bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.British journal of pharmacology · 2011Article
- Structure and activity of alpha-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABA(B) receptor-coupled N-type calcium channels.The Journal of biological chemistry · 2011Article
- Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.Bioorganic & medicinal chemistry letters · 2010Article
- Alpha9 nicotinic acetylcholine receptors and the treatment of pain.Biochemical pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.